Barclays raises Edwards Lifesciences stock price target on EBITDA outlook By Investing.com

Barclays raised Edwards Lifesciences' price target to $110 from $104 and kept an Overweight rating, citing a higher next-twelve-month EBITDA estimate of $2.44 billion versus $2.34 billion and a 24.0x EV/EBITDA valuation. The company also posted Q1 2026 revenue of $1.65 billion and adjusted EPS of $0.78, both above consensus, with TAVR sales of $1.197 billion beating estimates by $33 million. Additional support came from a $500 million accelerated share repurchase, though other brokers remain mixed on valuation.

Analysis

EW is getting upgraded for the right reason, but the more important signal is that estimate revisions are still moving faster than the stock can rerate. A higher EBITDA estimate combined with a still-below-history multiple implies the market is not yet paying for the durability of its growth, especially if TAVR mix remains strong and buybacks continue to compress share count. The second-order winner is the rest of the structural heart ecosystem: a healthy EW print typically tightens the funding/valuation window for adjacent med-tech names and makes “quality growth at any price” less punitive in the sector.

The near-term setup is less about the quarter and more about whether consensus has to chase again over the next 1-2 reporting cycles. If revenue growth stays mid-to-high single digits and management keeps converting operating discipline into cash returns, the stock can grind toward a premium multiple closer to its historical band. The risk is that the current rerate becomes self-limiting: at this valuation, any slowdown in procedure growth, reimbursement noise, or a moderation in FX/buyback tailwinds would likely compress the multiple before fundamentals fully roll over.

The contrarian view is that the market may be underestimating the durability of the moat, but overestimating the immediate upside from earnings beats. In other words, the stock is likely less a “breakout” and more a slow re-rating story unless management can show a clear acceleration in underlying procedure demand. That makes the best risk/reward in the name asymmetrical on pullbacks, not after analyst target resets.

From a competitive perspective, strong execution at EW can pressure smaller structural heart players by forcing a valuation comparison against a proven cash-generative leader. It also raises the bar for any competitor relying on future share gains rather than current profitability, which may matter more in a tighter capital market.

Key Decisions for Investors

• Maintain/add EW on 3-5% pullbacks over the next 2-4 weeks; upside is a drift toward Barclays’ $110 target, while downside is limited unless next-quarter procedure growth decelerates materially.
• For options, buy EW 3-6 month call spreads struck near current spot to the low-$100s; this captures further estimate revisions without paying full multiple expansion premium.
• Pair trade: long EW / short a weaker-capitalized structural-heart peer basket for 1-2 quarters; thesis is that quality cash flow and buybacks should outperform as the sector is forced to differentiate on execution.
• If EW trades above the revised target on no new fundamental upside, trim 25-30% and wait for the next earnings cycle; at this valuation, incremental upside depends on continued beat-and-raise behavior.
• Watch for a reversal trigger: any sign of TAVR growth slowing or buyback cadence pausing should be treated as a multiple-risk event rather than an earnings-risk event.